Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update
Release Date: 08/26/2026
Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update
ASCO Guidelines
Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on a patient's risk of recurrence, moving away from a one-size-fits-all model. They detail the recommendations for low, intermediate, and high-intensity surveillance groups, review the current role of blood-based biomarkers like ctDNA, and clarify the guideline's stance on supplemental imaging such as MRI and ultrasound....
info_outline
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0
ASCO Guidelines
Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based on mixed clinical trial results. Drs. Lesnock and Bouberhan emphasize the importance of an...
info_outline
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.2
ASCO Guidelines
Dr. Sonam Puri joins the podcast to share the update to the living guideline on stage IV NSCLC with driver alterations. Dr. Puri discusses the practice-changing evidence reviewed for both NTRK rearrangements, including the TRIDENT-1 trial, and HER2 activating mutations, including the Beamion LUNG-1 study. She shares how these results impacted the clinical practice guideline with the addition of repotrectinib and zongertinib, what these new TKIs mean for patients, and where the panel is waiting for additional randomized data to clarify the role of therapeutic options. Dr. Puri encourages...
info_outline
Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1
ASCO Guidelines
Dr. Rahul Banerjee joins the podcast to discuss the latest update to the living guideline on the treatment of multiple myeloma. He explains how sensational results from the MajesTEC-3 trial, which evaluated teclistamab plus daratumumab, prompted a major shift in the recommendations for patients with relapsed or refractory disease. Dr. Banerjee details why immunotherapies, specifically CAR T-cell therapy and bispecific antibodies, are now the preferred treatment options at first relapse over traditional triplets. He also provides context on evidence that did not lead to recommendation changes,...
info_outline
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline
ASCO Guidelines
Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be offered—including scenarios where tissue biopsies are challenging, unsafe, or unavailable in time to guide management—and explicitly outline situations where testing should not be utilized. They dive into the evidence evaluating ctDNA for treatment selection, molecular residual disease (MRD), and response monitoring across solid tumors and lymphoma. Drs. Lockwood and Gray explain the importance...
info_outline
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2
ASCO Guidelines
Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and...
info_outline
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 1
ASCO Guidelines
Dr. Lyudmila Bazhenova joins the podcast to share the update to the living guideline on stage IV NSCLC without driver alterations. Dr. Bazhenova discusses the evidence reviewed for both non-squamous NSCLC, including the POD1IM-304 and BAP BRAIN trials, and squamous cell NSCLC, including the HARMONi-6 trial. She shares how these results impacted the clinical practice guideline, what they mean for patients receiving immunotherapy and chemotherapy, and where the panel is waiting for additional evidence to clarify the role of therapeutic options. Dr. Bazhenova encourages listeners to stay tuned...
info_outline
Systemic Treatment of Thyroid Cancer Guideline
ASCO Guidelines
Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors (MKIs), genomically targeted therapies, immunotherapy, and cytotoxic chemotherapy across four subtypes of thyroid cancer: well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. He dives into the evidence supporting each recommendation and explains the importance of shared decision-making on the risks and benefits of each treatment...
info_outline
Patient-Clinician Communication Guideline Update
ASCO Guidelines
Dr. Timothy Gilligan and Dr. Calvin Chou discuss the updated guideline on patient-clinician communication in oncology. They highlight clinical recommendations and strategies on topics such as communication skills and practices that apply at every visit, principles for telehealth interactions, cross-disciplinary communication, facilitating involvement of the patient’s support network, discussing prognosis, goals of care, treatment selection – including clinical trials, end-of-life discussions, overcoming barriers to communication, facilitating discussions of cost of care and financial...
info_outline
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update
ASCO Guidelines
Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the...
info_outlineDrs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on a patient's risk of recurrence, moving away from a one-size-fits-all model. They detail the recommendations for low, intermediate, and high-intensity surveillance groups, review the current role of blood-based biomarkers like ctDNA, and clarify the guideline's stance on supplemental imaging such as MRI and ultrasound. The co-chairs emphasize the importance of shared decision-making between clinicians and patients and discuss how these updated recommendations aim to improve quality of life and reduce unnecessary testing for breast cancer survivors.
Read the full guideline, "Breast Cancer Follow-up and Surveillance after Primary Treatment: ASCO Guideline Update," at www.ascopubs.org/topics/asco-guidelines/breast-cancer"